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Lesch-Nyhan disease (LND) is a severe neurological disorder caused by loss-of-function mutations in 
the gene encoding hypoxanthine phosphoribosyltransferase (HPRT), an enzyme required for efficient 
recycling of purine nucleotides. Although this biochemical defect reconfigures purine metabolism and 
leads to elevated levels of the breakdown product urea, it remains unclear exactly how loss of HPRT 
activity disrupts brain function. As the rat is the preferred rodent experimental model for studying 
neurobiology and diseases of the brain, we used genetically-modified embryonic stem cells to generate 
an HPRT knock-out rat. Male HPRT-deficient rats were viable, fertile and displayed normal caged 
behaviour. However, metabolomic analysis revealed changes in brain biochemistry consistent with 
disruption of purine recycling and nucleotide metabolism. Broader changes in brain biochemistry were 
also indicated by increased levels of the core metabolite citrate and reduced levels of lipids and fatty 
acids. Targeted MS/MS analysis identified reduced levels of dopamine in the brains of HPRT-deficient 
animals, consistent with deficits noted previously in human LND patients and HPRT knock-out mice. 
The HPRT-deficient rat therefore provides a new experimental platform for future investigation of how 
HPRT activity and disruption of purine metabolism affects neural function and behaviour.
Lesch-Nyhan Disease (LND) is a neurological disorder in humans that primarily affects men and is caused by 
mutations in the X-linked Hprt gene encoding hypoxanthine phosphoribosyltransferase (HPRT)1,2. This protein 
is a key component of the purine salvage pathway and its loss in LND patients is associated with excessive uric 
acid (hyperuricaemia), which causes kidney damage and gout in affected patients. LND is also associated with 
deficits in motor and cognitive capabilities and self-harming behaviour. Many symptoms can be controlled with 
drugs that reduce the level of uric acid in the blood (allopurinol). However, this treatment does not satisfactorily 
alleviate neurological or behavioural problems, implying that chronic hyperuricaemia is not directly responsible 
for these symptoms3. Moreover, a subset of patients carrying mutations in HPRT suffers from hyperuricaemia 
but does not exhibit significant neurological deficits. This could imply that loss of HPRT activity affects other 
important molecular pathways, a notion that is supported by the finding that the basal ganglia within the brains 
of LND patients have markedly reduced levels of the neurotransmitter dopamine4. The significance of this deficit 
is not entirely clear, but depletion of catecholamine- (including dopamine) containing neurons in the brains of 
newborn rats can also induce self-injurious behaviour upon administration of L-DOPA5. Although treatment 
with dopamine receptor antagonists lessened symptoms in these animals, treatment of LND patients with recep-
tor antagonists had no beneficial effects on self-injurious behaviour. There is, therefore, a pressing need to develop 
new animal models to investigate the biochemistry and biology associated with loss of HPRT.
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The location of Hprt on the X-chromosome, and the ability to select for loss or gain of HPRT function 
through selection using synthetic nucleotide analogues, made the Hprt gene an attractive target for the first gene 
knock-out experiments in mice using embryonic stem cells6,7. The resulting HPRT knock-out mice had reduced 
levels of dopamine in the striatum, consistent with data obtained from human patients4,8–10. However, loss of 
HPRT activity in mice did not induce the classic neurological symptoms associated with LND. This has been 
attributed to a number of factors, including species-specific differences in the operation of the purine salvage 
pathway that may limit neurological damage in the mouse brain11. It is also possible that subtle disturbances of 
neuronal development and function might be more readily detected in a behaviourally sophisticated experimen-
tal animal like the rat.
The laboratory rat is a popular experimental animal in many biological studies due to its convenient size, 
physiology and genetics, and is widely regarded as a useful model for brain and behavioural studies12,13. Although 
targeted genetic modification in rats to study gene function and model human disease has lagged behind that 
performed in the mouse, recent innovations using embryonic stem cells and gene-specific synthetic endonucle-
ases have reignited interest in applying targeted genetic engineering in the rat14–17. In this report we describe the 
generation of a line of HPRT-deficient rats that exhibit metabolic and dopamine deficits associated with LND and 
should, therefore, provide a useful alternative experimental foundation for pharmacological and genetic studies 
into how HPRT deficiency affects the nervous system and behaviour.
Results
Generation of HPRT-deficient transgenic rats. Guided by previous reports, we designed a DNA target-
ing construct that inactivates HPRT function through deletion of exons 7 and 8 of rat Hprt18,19. The Hprt targeting 
vector contained 2.5 kb 5′ and 2.2 kb of 3′ genomic DNA surrounding a phosphoglycerate kinase (PGK) pro-
moter-driven neomycin selection cassette flanked by frt recombination sites, replacing exons 7 and 8 of rat Hprt 
(Fig. 1a). We electroporated two germline competent DA (dark agouti) rat ESC lines with the linearised targeting 
vector: DAK31 is a male line derived in 2i + LIF culture20 and DA27 is female line derived in our laboratory using 
MEK inhibitor only (1i) culture medium21. Two days after electroporation ESCs were switched to medium con-
taining the aminoglycoside G418, and after a further 7–9 days of selection, stably-transfected G418-resistant ESC 
colonies were picked and expanded. The clones generated from the male DAK31 cell line were plated in duplicate 
and one set was treated with 6-thioguanine (6-TG). This purine analogue is converted by HPRT to 6-thioguanine 
monophosphate which inhibits the synthesis and utilisation of purines and cell growth, thereby allowing the 
functional identification of HPRT-deficient clones. PCR genotyping and subsequent southern blot analysis, using 
5′ and 3′ external probes from genomic regions flanking the 5′ and 3′ homology arms, identified one DAK31 
and four DA27 clones carrying a correctly disrupted Hprt gene (HprtΔex7,8). This represented targeting frequen-
cies (number of targeted colonies/cells electroporated) of 0.1 × 10−6 and 0.4 × 10−6 for DAK31, and DA27 lines 
respectively, which are comparable with those previously obtained with Fischer F344 and SD rat ES cell lines19.
Based on ESC colony morphology, embryoid body differentiation22, and retention of a karyotype similar to 
that of the parental cell line, we selected targeted clones DA27-E1 and DAK31-4B12 for blastocyst injection to 
generate ESC-derived chimaeras. The DA27-E1 and DAK31-4B12 clones produced coat colour chimaeras at 
a frequency of 48% and 26% of live born pups generated from embryo transfers, respectively (Supplementary 
Table S1). The male DAK31-4B12 chimaeras were mated with SD females and resulting F1 germline females were 
bred with SD males to transmit the HprtΔex7,8 allele to male HPRT-deficient rats. (Fig. 1b,c). Male pups from a 
female DA27-E1 chimaera carrying the ESC HprtΔex7,8 allele were also identified (Fig. 1b,c). Western blots of rat 
brain tissue probed with anti HPRT antibody confirmed the absence of HPRT protein in male rats carrying the 
targeted HprtΔex7,8 allele (Fig. 1d). HPRT-deficient male rats from both clones appeared healthy and were fertile. 
DAK31-4B12 derived animals were used to establish a line of HprtΔex7,8 transgenic rats. These rats attained the 
same weights as matched wild-type littermates (Supplementary Fig. S1) and displayed normal caged behaviours.
Metabolomic analysis of the brains of HPRT-deficient rats. Loss of HPRT has direct effects on purine 
synthesis, principally through the loss of the salvage pathway that converts hypoxanthine and guanine to inosine 
monophosphate and guanine monophosphate, respectively (Fig. 2). In Lesch-Nyhan patients lacking HPRT activ-
ity, the resulting excess hypoxanthine and xanthine leads to elevated levels of uric acid1,2. By contrast, in most 
other animals including rats, the presence of an active uricase enzyme limits the build-up of uric acid23. Indeed, 
the levels of uric acid we measured in HPRT KO rats were indistinguishable from wild-type animals and similar 
to basal levels reported previously24 (Supplementary Fig. S2). The loss of the purine salvage pathway, however, 
leads to increased levels of de novo purine synthesis and is expected to have wider consequences for other met-
abolic processes. To obtain an overview of how HPRT loss affects metabolism in the rat brain we compared the 
metabolic profile of two regions of wild-type and HPRT knock-out (KO) male rat brains (Supplementary Fig. S3) 
by liquid chromatography-mass spectrometry (LC-MS). The central area (region A) contained the hippocam-
pus, overlying cortex, striatum and hypothalamus, and encompassed areas of the brain that in HPRT-deficient 
mice have previously been shown to have reduced levels of dopamine8,10,25. The forebrain area largely contained 
olfactory bulb and cortex (region B). Brain samples from four wild-type and four HPRT KO male rats were 
homogenised in chloroform/methanol solution and snap frozen in liquid nitrogen for storage before LC-MS 
analysis. The metabolic profiles of brain extracts from wild-type and KO rats unambiguously identified 69 core 
metabolites and assigned putative identities to an additional 675 compounds based on accurate mass measure-
ments and retention time predictions, from which elemental compositions were calculated26 (Supplementary 
Table S2). To identify metabolites that were affected consistently by the loss of HPRT activity, we compared 
the areas under the peaks in LC-MS extracted ion chromatograms of the putative metabolites. The levels of 
36 metabolites were altered in both regions A and B within HPRT-deficient brains (Supplementary Table S3). 
Two compounds, citrate and orotidine, were positively assigned through matches with standards whilst the 
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others were predicted from accurate mass/retention time data. To confirm correct assignment of identities to 
the other 34 compounds, we reanalysed samples by targeted MS/MS analyses, searched the resulting data against 
publically-available spectral libraries and also submitted data to the in silico calculation tool MetFrag27. Twenty 
metabolites had elements within their MS/MS spectra that were consistent with molecular assignments made in 
the initial LC-MS analysis (Table 1). Within this set the level of N-formiminoglycine, a derivative of the HPRT 
substrate hypoxanthine, increased in HPRT-deficient rat brains (Fig. 2). Deoxyinosine, 5-amino-4-imidazole car-
boxylate and 5′ -phosphoribosyl-glycinamide, which are also associated with purine metabolism, were identified 
in the original LC-MS analysis as consistently higher in HPRT KO rat brains, but MS/MS spectra for these com-
pounds could not be acquired. Interestingly, compounds exhibiting statistically significant increases in one or 
other of the brain regions of HPRT KO animals included the pyrimidine derivatives UMP and CMP, the second 
messenger cAMP and glucose-6-phosphate (Fig. 3 and Supplementary Tables S3–5). These increases, and those 
of citrate and orotidine, were accompanied by reduced levels of lipids and fatty acids in HPRT KO rats (Fig. 3 and 
Supplementary Tables S3–5). Therefore, the loss of HPRT activity in rats leads to altered levels of compounds 
associated with nucleotide metabolism and wider changes in general metabolism in the brain.
Figure 1. Generation of HPRT-deficient rats. (a) Structure of the HPRT targeting vector (top), the wild-type 
Hprt allele (middle) and targeted allele (bottom), resulting from replacement recombination at the dotted lines. 
The null allele was created by substitution of exons 7 and 8 with an frt-flanked PGKneo selection cassette (green 
box with yellow arrows). Exons are depicted by red boxes, non-exon–containing chromosomal, and cloned 
genomic DNA sequence is shown by a thick black line and pBluescript plasmid sequence by a thin black line. 
Restriction enzyme sites BstBI (Bs), EcoRV (E), NdeI (N), SacI (S) and XbaI (X) are indicated. 5′ and 3′ probe 
sequences (dark and light hashed boxes respectively), external to the homology arms were used for Southern 
blot screening. The size of expected products are shown by dotted arrows. (b) Southern blot analysis using the 
5′ external probe on genomic DNA of wildtype (WT) ES cells, targeted (Tg) ESC sub-clones and HPRT KO rats 
from 2i + LIF-derived DAK31 and 1i-derived DA27 cell lines (left and right panel respectively). (c) Southern 
blot analysis using the 3′ external probe on genomic DNA samples as described for (b). (d) Western blot 
analysis of HPRT protein expression in male wild-type and HPRT knock-out (KO) ESC lines, and brains of two 
wild-type rats (SD and DA) and two HPRT KO male rats.
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Analysis of the level of monoamines in brains of HPRT-deficient rats. LND and HPRT deficiency 
in mice is associated with loss of dopamine in areas of the brain4,8–10. To examine how loss of HPRT activity in 
the rat also affects the level of dopamine and its metabolites, or other monoamine neurotransmitters, we per-
formed targeted HPLC-MS analysis on acetonitrile extracts prepared from 6 regions (I–VI) within the brains 
of nine wild-type and seven HPRT KO deficient males rats (Supplementary Fig. S4). Variation in the levels of 
the neurotransmitters tested (dopamine, dihydroxyphenylacetic acid, epinephrine, norepinephrine, tryptophan, 
serotonin, kynurenine, hydroxykynurenine, hyrdoxyanthranilic acid, and γ -aminobutyric acid) were observed 
between the different brain regions, but in most cases these did not differ significantly between wild-type and 
KO rats (Supplementary Fig. S5, Table S6). In contrast, dopamine and serotonin levels in region V containing the 
hippocampus and striatum were reduced by as much as 50% in comparison to control brain samples (Fig. 4). To 
determine whether the loss of dopamine was associated with changes in dopaminergic neurons or reduced levels 
of tyrosine hydroxylase (TH), a key enzyme in the synthesis of dopamine, we performed TH immunostaining on 
coronal sections of male wild-type and knock-out rat brains (Supplementary Fig. S6). The intensity and distribu-
tion of TH staining in KO rat brain sections was normal and similar to the wild-type controls, indicating that loss 
of dopamine was unlikely to be attributable to reduced levels of TH or TH-expressing neurons, and is in line with 
similar results previously reported for HPRT-deficient mice10,25.
Discussion
Mutation of the HPRT gene causes severe neurological deficits in Lesch Nyan patients, and recapitulating this 
genetic lesion in mice has provided insights into some aspects of this debilitating disease23. Mutation of the Hprt 
gene has also served as a useful component in genetic engineering protocols because of the gene’s accessibility to 
transgene integration by homologous recombination, amenability to positive and negative selection schemes, and 
neutral character as a “harbour” for regulated transgene expression28,29. Here we have described targeted disrup-
tion of Hprt in independent rat ESC lines propagated in either the standard dual inhibitor (2i + LIF) or a single 
inhibitor (1i)-type culture system, and used the targeted clones to generate transgenic rats. We have established 
that brains of HPRT-deficient rats exhibit changes in levels of neurotransmitters and metabolites, and therefore 
propose that HPRT knock-out rats represent a new experimental platform to investigate the function of HPRT 
in the brain and LND.
The first successful derivation of rat ESC cultures was built on the discovery that dual chemical inhibition 
of MEK and GSK3 signalling pathways blocks mouse ESC differentiation15,16,30. This two-inhibitor (2i) culture 
system facilitated efficient establishment of rat ESC lines and allowed the implementation of gene targeting in the 
rat by homologous recombination17,19,31. Compared with mouse stem cell lines, however, rat ESC cultures were 
less stable, partly due to their different pattern of response to GSK3 inhibition in 2i-type medium21,32. Indeed, 
we previously showed that efficient de novo derivation and expansion of rat ESC lines could be achieved using 
the MEK inhibitor alone (1i culture) on fibroblast feeder cells, obviating the requirement for chemical inhibition 
of GSK321. We have extended this observation by showing that a cell line propagated in this 1i condition can be 
genetically modified, undergo clonal selection/expansion and still retain the capacity to transmit a targeted muta-
tion through the rat germ line. This highlights the scope for tuning the standard 2i culture regimen to assist the 
derivation of rat ESC from more refractory rat strains, or provide opportunities for differential priming of ESC 
signalling prior to exit from pluripotency.
Transmission of the HprtΔex7,8 allele through the germ line and establishment of HPRT-deficient transgenic 
rats allowed us to examine for the first time, how loss of HPRT activity affected biochemistry in the rat brain. 
Consistent with the role of HPRT in recycling hypoxanthine and guanine, our analysis revealed changes in levels 
of compounds associated with purine metabolism. We also detected increases in the amounts of non-purine 
Figure 2. The role of HPRT in the purine salvage pathway. HPRT plays a central role in generating 
purine nucleotides by catalysing the conversion of hypoxanthine and guanine to inosine monophosphate 
(IMP) and guanine monophosphate (GMP) respectively. The de novo purine synthesis pathway via 
phosphoribosylpyrophosphate (PRPP) is also highlighted.
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nucleotides, such as UMP and CMP, in line with elevated levels of pyrimidines previously identified in 
HPRT-deficient brain tissue and neuronal cell cultures33–35. It is noteworthy that the level of orotidine, a derivative 
of the UMP precursor, orotic acid, was also higher in the HPRT-deficient rat brains. Elevated levels of orotidine 
have been reported in blood cells of LND patients, and in response to treatment with the drug allopurinol, a 
hypoxanthine analogue that blocks the breakdown of xanthine to urea36,37. Although this implicates hypoxan-
thine as a regulator of pyrimidine metabolism, there was no evidence for higher levels of hypoxanthine in brains 
of HPRT KO rats. Nevertheless, levels of the second messenger cAMP, which in other experimental systems are 
affected by hypoxanthine38–40 , were also increased in HPRT KO rat brains. This increase contrasts with the reduc-
tion in cAMP-dependent signalling reported in HPRT-deficient cell lines41,42, but might reflect the challenges 
associated with aligning in vitro responses with the physiological state in vivo. For example, glucose concentration 
affects the inhibitory effect of hypoxanthine on preimplantation embryonic development39,43. The changes in core 
metabolites we report here, such as increases in level of glucose-6 phosphate and citrate, and decreases in lipids 
and fatty acids, may result from an increased metabolic demand in vivo due to compensatory de novo nucleotide 
synthesis in the brain. Perhaps, these direct and indirect consequences of HPRT loss, converge to perturb neural 
function in the HPRT-deficient brain.
Reduced levels of dopamine and serotonin in the brains of HprtΔex7,8 rats confirmed that loss of HPRT activity 
disturbed normal neuronal function in the rat. The depletion of dopamine in HPRT KO rat brains approached 
60% of wild-type levels and given that these brain samples had contributions from overlying cortex, the hip-
pocampus and the striatum, the losses in individual areas might be significantly greater. In human LND patients 
the reduction in dopamine was 70–90% of normal levels and in HPRT-deficient mice losses ranged between 
20–60% depending on the strain, which might impact on modelling neurological deficits associated with 
LND4,8,25,44. Interestingly, the reduced level of serotonin in HPRT KO rat brains was consistent with results from 
one of the first HPRT KO studies in mice, and points to a broader deregulation of neurotransmitters associated 
with HPRT loss25. Indeed, although a similar deficit was not evident in the post-mortem brains of LND patients4, 
temporary alleviation of self-injurious behaviour in response to treatments that increase serotonin levels, and 
reduced levels of serotonin receptors in LND patients point to an association between serotonin and HPRT func-
tion45,46. Taken together these results indicate that loss of HPRT activity has wider effects on neurotransmitters 
than just dopamine, possibly a consequence of the widespread metabolic changes in the HPRT-deficient brain.
In conclusion, although HPRT KO male rats appear generally healthy and fertile, the biochemical analysis of 
the HPRT-deficient brains pointed to potentially widespread perturbation of general metabolic processes beyond 
disruption of purine metabolism. Moreover the reduction of dopamine and serotonin within HPRT KO brains 
mirrors aspects of studies performed on LND patients and HPRT KO mice4,8,25,44. The HPRT knock-out rat there-
fore serves as a new experimental platform to investigate how loss of HPRT activity affects neural function during 
Kegg ID Compound Pathway
Validation 
level*
Region A 
KO:WT 
ratio
Region A 
t-test
Region B 
KO:WT 
ratio
Region B 
t-test
C02718 N-Formiminoglycine nucleotide metabolism 3 n/a 0.003 30.545 0.001
– Orotidine nucleotide metabolism 1 2.417 0.012 2.903 0.028
C03366 5-Phosphonooxy-L-lysine amino acid metabolism 3 n/a 0.010 n/a 0.006
C01035 4-Guanidinobutanoate amino acid metabolism 2 1.431 0.020 1.542 0.016
C00158 Citrate carbohydrate metabolism 1 1.792 0.026 2.210 0.036
C00416 LPA(0:0/18:1(9Z)) lipid metabolism 2 0.681 0.048 0.660 0.008
C06424 Tetradecanoic acid lipid metabolism 3 0.654 0.016 0.674 0.015
C08362 (9Z)-Hexadecenoic acid lipid metabolism 3 0.533 0.008 0.660 0.017
C00712 [FA (18:1)] 9Z-octadecenoic acid lipids: fatty Acyls 3 0.489 0.019 0.645 0.014
C06429 Docosahexaenoicacid lipids: fatty Acyls 2 0.452 0.040 0.567 0.005
C16522 Icosatrienoic acid lipids: fatty Acyls 2 0.376 0.010 0.515 0.010
C16527 [FA (22:4)] 7Z,10Z,13Z,16Z-docosatetraenoic acid lipids: fatty Acyls 2 0.355 0.023 0.551 0.005
C11896 Docosapentaenoic acid (Taxa-4(20),11(12)-dien-5alpha-yl acetate) lipids: fatty Acyls 2 0.333 0.021 0.437 0.001
– [GP (20:4)] 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate lipids: glycerophospholipids 3 0.509 0.012 0.543 < 0.001
– LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) lipids: glycerophospholipids 3 0.415 0.045 0.643 0.037
– LysoPE(0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) lipids: glycerophospholipids 3 0.345 0.006 0.482 0.005
– [PE (20:4)] 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine lipids: glycerophospholipids 3 0.338 0.008 0.439 0.001
C16621 1-Methyl-4-nitroimidazole n/a 3 n/a 0.000 n/a 0.008
– DL-2-Aminooctanoicacid n/a 2 3.038 0.033 3.549 0.034
C01546 2-Furoate n/a 2 1.802 0.013 2.381 0.030
Table 1.  Altered levels of 20 metabolites in brains of HPRT knock-out rats. The changes in levels of 20 
metabolites that differed in both regions A (Cortex, hippocampus, striatum and hypothalamus) and region B 
(olfactory bulb and pre-frontal cortex) of HPRT-deficient rat brains. The MS/MS spectra of these compounds 
had elements that were consistent with molecular assignments made in the LC-MS analysis. Validation 
confidence levels are 1. Match to a known standard; 2. MS/MS data matches to a public library with score of >0); 
3. MS/MS data matches by In Silico (MetFrag) approach with score > 0).
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embryonic development and in adult animals. We suggest that elaboration of this model through the introduction 
of secondary genetic modifications in associated regulatory pathways should provide further opportunities to 
dissect mechanisms underlying Lesch-Nyhan Disease.
Figure 3. Altered brain metabolism in brains of HPRT-deficient rats. Graphs describing LC-MS analysis of 
select metabolites that differ between wild-type and HPRT-deficient rat brains in either region A (containing 
hippocampus, overlying cortex, striatum and hypothalamus) and/or region B (containing olfactory bulb and 
pre-frontal cortex). The graphs represent mean mass spectral counts +/− SD obtained from analysis of brains 
from 4 HPRT wild-type and 4 HPRT KO male rats. The values of most metabolites in WT and KO animals for 
a particular region differed (p < 0.05). Exceptions were UMP and 3′,5′ -Cyclic AMP in region B, and D-Glucose 
6-phosphate in region A.
www.nature.com/scientificreports/
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Methods
Ethics statement. Animal work conformed to guidelines for animal husbandry according to the UK Home 
Office and approval by the Roslin Institute Animal Ethics Committee. Animals were naturally mated and sacri-
ficed under schedule 1, procedures that do not require specific Home Office approval.
Derivation and culture of rat ES cells. ES cell derivation and culture were as previously described with 
minor modifications21. Cells were cultured on gamma-irradiated (5 Gy) DIA-M or DR4 mouse fibroblasts in: 1i 
medium; N2B27 + 1 μ M PD0325901 (Axon Medchem) or 2i + LIF medium; N2B27 + 1 μ M PD0325901 + 3 μ M 
CHIR99021: (Axon Medchem) + 103 units/ml mouse Leukaemia Inhibitory Factor (Millipore).
Targeting vector construction. A 6.9 kb fragment was amplified from Fischer F344 Rat genomic 
DNA using oligonucleotides flanking Exons 7, 8 and 9 (HPRTintr6for2 - CCTCCCCAATGCCTACAATG 
and 3′ FLKrev3 – CCTTTCCCTGTCCTACACAC). The PCR was performed using Pfu UltraII Fusion HS 
DNA Polymerase (Stratagene) under the following conditions; 95 °C for 2 mins, followed by 30 cycles of 94 °C 
for 30 secs, 60 °C for 30 secs and 68 °C for 10 mins, with a final extension at 68 °C for 10 mins. PCR products 
were cloned into EcoRV digested pBluescript and sequence integrity was confirmed by comparing sequences 
of four individual clones from separate PCR reactions with the sequence for Brown Norway rat (Ensembl, 
ENSRNOG00000031367). A 5.4 kb BstBI/SacI fragment was subcloned from the F344 HPRT PCR clone. The 
650 bp NdeI/EcoRV fragment containing exons 7 and 8 was removed and replaced with a selection cassette con-
sisting of PGKneo flanked by frt recombination sites.
Electroporation. Approximately 1 × 107 rat ES cells in 0.8 ml phosphate buffered saline (PBS) containing 
75 μ g AhdI linearised HPRT targeting vector were electroporated using the Bio-Rad Genepulser apparatus (0.8 kV, 
3 μ F). Electroporated cells were plated into 10 cm2 wells containing 2i + LIF (DAK31) or 1i (DA27) medium. The 
aminoglycoside G418 (150 μ g/ml) was added 48 h after electroporation and the number of G418-resistant colo-
nies counted 7 or 8 days later. 6-TG (5 μ M) was applied at either day 9 or following picking and replica-plating of 
individual G418-resistant clones.
Figure 4. Effect of HPRT deficiency on the levels of dopamine and serotonin in rat brain. HPLC analysis of 
(a) dopamine and (b) serotonin in regions I–VI in the brains of wild-type and HPRT knock-out (KO) rats.  
(I: Olfactory bulb; II: hypothalamus; III: Pre-frontal Cortex; IV: Midbrain; V: Hippocampus, cortex and 
striatum; VI: Cerebellum. Y axis values represent means obtained from analysing 9 HPRT wild-type and 7 
HPRT KO brain samples +/− SD. White and grey bars represent wild-type control and KO values, respectively.
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Karyotype analysis. Cells were cultured for two hours in 0.1 mg/ml colcemid (Life Technologies), swollen 
in 0.56% (w/v) KCl hypotonic solution and fixed on ice in 3:1, methanol:acetic acid. Metaphase spreads were 
prepared on glass slides and stained with Giemsa (Life Technologies).
Chimaera generation. Rat blastocysts at E4.5 days post-coitum were cultured for 2–3 hours in M16 embryo 
culture medium (Sigma) to ensure cavitation, prior to injection. Rat ESC were disaggregated in TVP trypsin 
solution22 , pelleted in 1i/2i N2B27 culture medium and pre-plated on gelatin-coated tissue culture plastic in 1i/2i 
for 45–60 mins. Non-attached cells were pelleted and resuspended in N2B27 containing 20 mM HEPES buffer 
and kept on ice prior to injection. Blastocysts were transferred to M2 medium (Sigma) before injection with 
10–12 cells, and then transferred into the uteri of pseudopregnant Sprague Dawley rats.
Genomic PCR screening. 100 ng of genomic DNA was amplified using oligonucleotides designed to iden-
tify the wildtype allele (Ex7for - GTGTTGGATACAGGCCAGAC and Ex8rev - GTGCTCATTATAGTCAAGGG) 
and the  targeted a l le le  (HPRT2524for  –  CT TCTCCCT T TCAGTCT TCC and PGKrev – 
GATGTGGAATGTGTGCGAGG). The PCR was performed using FastStart Taq (Roche) under the following con-
ditions; 95 °C for 2 mins, followed by 33 cycles of 95 °C for 30 secs, 55 °C for 45 secs and 72 °C for 10 mins, with a 
final extension at 72 °C for 10 mins. Products were separated by 1% TBE agarose gel electrophoresis and visualised 
with ethidium bromide. The expected sizes of the wildtype and targeted alleles are 252 bp and 286 bp respectively.
Southern Blot. Eight to ten micrograms of genomic DNA were digested with 200 units of restriction 
enzyme at 37 °C for 30 hours. The resulting DNA fragments were resolved on a 0.7% TAE agarose gel overnight 
at 25 V. The DNA fragments were UV-nicked prior to transfer to Hybond N + Nylon membrane (GE Healthcare, 
RPN203B) as described in the manufacturer’s instructions. Following transfer, the DNA was UV cross-linked on 
to the membrane. Probes were prepared by PCR amplification of HPRT sequence flanking the 5′ and 3′ homol-
ogy arms (Intr6F2 – CCTCCCCAATGCCTACAATG and HPRT289R – GAAAAAGGAAGCAAGTGTGG, and 
HPRT6125F – GTGCTGTTTTCCTCATGGGC and HPRT6373R – GCTACCTTCTGGCTTTGTTAG for 5′ and 
3′ probes respectively).
25 ng of probe DNA was radioactively labelled with α –dCTP P32 using High Prime (Roche, 11 585 592 001), 
then hybridised to the membrane overnight at 65 °C in Church solution containing 10 μ g/ml sonicated Herring 
Sperm DNA and 10 μ g/ml tRNA. Non-specifically bound probe was removed by washing in 2× SSC/0.1% (w/v) 
SDS at 65 °C. The membrane was exposed to Kodak Biomax MS film at −80 °C.
Western Blotting. Western blot analysis was performed using Novex BisTris 12% precast PAGE gels run in 
MOPS buffer, transferred to Hybond-ECL nitrocellulose membranes, consecutively probed with primary anti-
bodies and fluorescently labelled secondary antibodies, diluted in Li-Cor blocking buffer and scanned using 
a Li-Cor Odyssey Scanner as recommended by the manufacturers. Antibodies used were: anti-HPRT (Abcam 
ab10479) and anti- γ -tubulin mab (Sigma-Aldrich, T5326).
Histology. Free floating immunohistochemistry was performed on brains from wild-type and 
HPRT-knockout adult male rats. Rats were kept in single cages with food and water ad libitum on 12-h light/
dark cycle (lights on 0700 h). The rats were killed between 2 and 5 h after lights on, and their brains were removed 
and hemi-dissected in the sagittal plane through the midline (Supplementary Fig. S3). Half of the brain was 
immersion fixed in 4% (w/v) paraformaldehyde in 0.1 M PBS solution (pH 7.4) for 7 days, post-fixed in 15% (w/v) 
sucrose in 4% (w/v) PFA overnight, cryoprotected in 30% (w/v) sucrose in 0.1 M PBS for a further 24 hours and 
snap-frozen on dry ice. The other half of the brain was used in the HPLC metabolomics study (see below). The 
brain was sectioned in the coronal plane at 50 μ m on a freezing microtome and then processed for immunohis-
tochemistry using a mouse anti-tyrosine hydroxylase (TH) monoclonal antibody (Millipore). The antibody was 
diluted to a concentration of 1:1000 in phosphate buffer (PB) with 0.2% (v/v) Triton X-100 and 3% (v/v) normal 
goat serum. Sections were incubated in TH antibody for 24 h at 4 °C. The antibody-antigen complex was localized 
and amplified using the ABC method with a Vector elite kit (Vector Inc). TH immunoreactivity was visualized 
using 0.025% (w/v) diaminobenzidine with 0.03% (v/v) hydrogen peroxide, adapted from47. Following washes in 
PB, sections were mounted onto gelatin-coated slides, air dried, dehydrated through an alcohol series and sealed 
with using a coverslip with Pertex mounting medium (Leica Microsystems).
Analysis of Uric Acid in rat serum. Rat blood was harvested immediately from freshly culled and decapi-
tated adult rats. 1 ml of blood was placed in a 1.5 ml-coated clotting tube, mixed gently by inversion and incubated 
for 45 minutes at room temperature. Serum was harvested by centrifugation for 15 minutes at 1300 × g. Serum 
was carefully removed by pipette and transferred to a fresh tube. Cellular debris was removed by centrifugation 
for a further 15 minutes at 1300 × g. Uric acid analysis was performed using a colorimetric peroxidase-coupled 
indirect equilibrium uricase method by Pinmoore Animal Laboratory Services Limited, Cheshire, UK.
Quantitation of selected neurochemicals. Prior to analysis, 16 brains (9 control, 7 knock-out) were 
sectioned into 6 areas according to the scheme shown in Supplementary Fig. S4. The basic methodology for neu-
rochemical quantitation follows that published previously48. Briefly, brain samples were homogenised in 20 mM 
Ascorbic acid (100 μ l per 50 mg tissue) using a handheld homogeniser (Fisher). To 125 μ l of homogenate was 
added 2 μ l of a 10 ng/μ l solution of caffeic acid, which acted as an internal standard to control for variations in 
extraction, and 500 μ l ice cold acetonitrile. The sample was vortexed and the precipitate removed by centrifuga-
tion (13,000 × g for 15 mins at 4 °C). The supernatant was evaporated under vacuum and the residue resuspended 
in 25 μ l of labelling buffer (100 mM sodium tetraborate). 25 μ l of labelling reagent (2% (v/v) benzoyl chloride in 
acetonitrile) was added and the reaction mixed at room temperature. Insoluble material was removed by centrif-
ugation (13,000 × g for 10 minutes at 4 °C) and the supernatant analysed by HPLC-MS.
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Neurochemicals were separated by use of an Ascentis Express HPLC column (C18, 2.1 mm id × 15 cm length, 
2.7 μ m bead size, Supelco) attached to a Dionex Ultimate HPLC system. The eluent was pumped through the col-
umn at a flow rate of 200 μ l/min (solvent A was 10 mM ammonium formate & 0.15% formic acid, solvent B was 
acetonitrile) and the separation was developed by a multipart gradient as follows: 0 mins – 20% B; 0.5 mins – 20% 
B; 2 mins – 45% B; 7.5 mins – 64% B; 8 mins – 100% B. This gradient was followed by a 3.5 minute hold at 100% B, 
followed by a reduction to 20% B and a 1 minute hold to re-equilibrate the column. The eluent was passed directly 
to the electrospray source of an Amazon ETD ion trap mass spectrometer (Bruker) operated in +ve ion, multi-
ple reaction monitoring mode. MS conditions for each analyte are provided (Supplementary Table S7). At least 
6-point standard curves of pre-labelled analytes in solvent A were built and samples were run in at least duplicate, 
in 7 batches. Data processing was performed using the Bruker Compass plugin, QuantAnalysis. Any effect of 
matrix on measurement of neurochemicals in the brain samples was corrected for by use of measured concentra-
tion of the internal standard, caffeic acid. Finally repeat measurements were averaged, and significant differences 
in the concentration of different analytes between KO and WT samples were revealed by student t-tests.
Metabolomic workflow, data acquisition and analysis. Dissected brain samples were flash frozen in 
liquid N2 and ground to a powder using a chilled pestle and mortar. Approximately 5 μ l volume of ground sam-
ple was solubilised in 200 μ l of chloroform/methanol/water solution (1:3:1) at 4 °C by vortexing. The lysate was 
mixed at 4 °C for 1 hr and then centrifuged for 3 minutes at 13,000 g at 4 °C. Approximately 180 μ l of the cleared 
supernatant was stored at − 80 °C prior to analysis by MS.
LC-MS. Samples (10 μ l) were analysed by hydrophilic interaction liquid chromatography (HILIC)-mass 
spectrometry (LC-MS) (UltiMate 3000 RSLC (Thermo Fisher, San Jose, California, USA) using a 150 × 4.6 mm 
ZIC-pHILIC column (Merck SeQuant, Umea, Sweden) running at 300 ul/min and an Exactive (Thermo Scientific) 
for MS detection. Buffers consisted of A: 20 mM ammonium carbonate (Sigma Aldrich) in H2O (Fisher Scientific) 
and B: acetonitrile (Fisher Scientific). The gradient ran from 20% A: 80% B to 80% A: 20% B in 15 min, followed 
by a wash at 95% A: 5% B for 3 min, and equilibration at 20% A: 80% B for 5 min. The Exactive was used to detect 
ions using a HESI-II interface with a source temperature of 150 °C and capillary temperature of 270 °C. Sheath gas 
flow rate was 40, Aux gas flow rate was 5 and sweep gas was 1. Each sample was injected simultaneous detection 
in positive ion and negative ion using polarity switching mode, the spray voltage was 4.5 kV and 3.5 kV respec-
tively. Full scan MS detection was acquired for the range 70–1400 m/z at 50000 (at 400 m/z) resolution mode 
for each polarity. Raw mass spectrometry data was processed using our standard pipeline, consisting of XCMS 
(for peak picking), MzMatch (for filtering and grouping) and IDEOM (for further filtering, post-processing and 
identification). Core metabolite identifications were validated against a panel of unambiguous standards using 
accurate mass and retention time. Additional putative identifications were assigned by accurate mass along with 
a retention time prediction algorithm.
LC-MS/MS. Samples (10 μ l) were separated by a SeaQuant ZIC-pHILIC 4.6 × 150 mm column (Merck) at 
a flow rate of 0.300 ml/min mobile phase. A gradient from 80% acetonitrile/20% 10 mM ammonium carbonate 
to 5% Acetonitrile/95% ammonium carbonate over 15 min was used to elute compounds. A 2 min hold at 5% 
acetonitrile was used to wash the column. The solvents were returned to initial conditions and held for 7 min for 
column re-equilibration. A QExactive (Thermo Scientific) was used to detect ions using a HESI-II interface. A 
source temperature of 150 °C and capillary temperature of 320 °C was used. Sheath gas, auxiliary gas and sweep 
gas flow rates of 40, 5 and 1 L/min were used. Polarity switching mode was used for detection. The spray voltage 
was 3.8 kV in either polarity. Full scan MS spectra were acquired for the range 70–1050 m/z with a resolution of 
70000 (at 400 m/z). A maximum of 5 ions selected from the precursor ion list were selected for MS/MS and were 
isolated using a 2 m/z window and activated with HCD at 60.0 NCE. Fragment ion spectra were acquired using a 
resolution of 35000 (at m/z 400). Fragment ion spectra were searched against online public databases, Massbank 
(http://www.massbank.jp/), mzCloud (https://mzcloud.org/) and Metlin (http://metlin.scripps.edu) and in sil-
ico fragmentation using MetFrag (http://msbi.ipb-halle.de/MetFrag/) searched against Kegg database. When no 
compounds were found from Kegg then PubChem and Chemspider was used as an alternative. All databases were 
searched using 20 ppm mass window for the fragmentation data.
Statistical Analysis. Metabolites identified in the LC-MS analysis were filtered to identify those that differed 
statistically (t-test p ≤ 0.05) in level between wild-type and mutant animals in the forebrain (region B) and cen-
tral region (region A) (Supplementary Tables S2, S3). The analyses were performed using two-tailed t-tests and 
normality assumptions for this test were satisfied. The selected metabolites that had elements within their MS/MS 
spectra that were consistent with molecular assignments made in the initial LC-MS analysis were analysed using 
ANOVA models to test the type (wild-type or HPRT KO) by area (regions A or B) interaction. This determined 
whether there was a significant difference (p ≤ 0.05) in the type effect between the brain areas. Where the type 
interaction was non-significant then the average of the region A and B brain areas was compared between the 
wild-type and mutant groups using a two-tailed t-test (Supplementary Table S8). Comparing the average level of 
validated standard compounds in wild-type and HPRT KO brains indicated there were increased levels of UMP, 
CMP, cAMP and glucose-6-phosphate in the brains of HPRT KO animals.
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